Cardiac Troponin Predicts Mortality in Acute Heart FailureDoctors LoungeA sensitive cardiac troponin I assay can predict mortality risk for patients with acute heart failure, according to a study published online Oct. 11 in the Journal of Internal Medi…
Study finds drop in heart failure hospitalizationsNurse.comBetween 1998 and 2008, heart failure-related hospitalizations declined substantially among Medicare patients, but at a lower rate for black men, according to a study. The study also found that …
Abbott Touts $4 Billion in Drug Sales as It Pitches SpinoffBusinessWeekDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business wi…
Commonly used 3-drug regimen for idiopathic pulmonary fibrosis found harmfulEurekAlert (press release)The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC)…
Heart failure strikes fewer seniorsAmerican Council on Science and HealthNow, a group of Yale researchers has found that the percentage of senior citizens hospitalized for heart failure has dropped by nearly one third since 1998. The study, published i…
Abbott Touts $4 Billion in New Drug Sales as It Pitches SpinoffBloombergDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business w…
Tehelka'No cure to UPA's multiple organ failure'Daily PioneerLed by the “weakest Prime Minister ever”, the UPA Government was suffering from a “multiple organ failure” and was showing all symptoms of a “terminal decline”, with i…
Jefferies Analysts Raise Alexion Pharmaceuticals (ALXN) EPS EstimatesLocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeuti…
Ocrelizumab Benefits in MS Maintained to 96 WeeksMedscapeRituximab, an anti-CD20 monoclonal antibody that selectively reduces CD20-positive B-cells, showed "proof of concept" efficacy in MS in phase 1 and 2 investigations, they say. Ocrelizum…
USA TodayAbbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1BWall Street JournalHowever, several of these drugs, including daclizumab, may not make it to market until around 2015, assuming successful clinical trials and regulatory appro…